CoChat

Pirfenidone for idiopathic pulmonary fibrosis

Bouros, Demosthenes · 2011 · The Lancet

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(11)60546-1

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 12 references

Cited by

See all 62

Metadata

Authors
Bouros, D.
Affiliations
Democritus University of Thrace (GR)
Corresponding author
Bouros, Demosthenes
Venue
The Lancet
Publisher
Elsevier BV
Published
2011-05
Volume
377
Issue
9779
Pages
1727-1729
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2091976584
Cited by
58
References
12
Citations by year
2026: 1 · 2025: 3 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 1 · 2017: 6 · 2016: 3 · 2015: 4 · 2014: 2 · 2013: 6 · 2012: 8
FWCI
5.70
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
pirfenidone, idiopathic pulmonary fibrosis, CAPACITY trial, forced vital capacity, progression-free survival, 6-minute walk test, drug safety and efficacy, antifibrotic therapy
MeSH terms
Anti-Inflammatory Agents, Non-Steroidal, Dose-Response Relationship, Drug, Europe, Exercise Test, Humans, Pyridones, Vital Capacity, Randomized Controlled Trials as Topic, Drug Approval, Clinical Trials, Phase III as Topic, Disease-Free Survival, Evidence-Based Medicine, Endpoint Determination, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pirfenidone for idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1016/s0140-6736(11)60546-1
The paper
Bouros, D. (2011). Pirfenidone for idiopathic pulmonary fibrosis. The Lancet. https://doi.org/10.1016/s0140-6736(11)60546-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.